Although much work has focused on the elucidation of somatic alterations that drive the
development of acute leukaemias and other haematopoietic diseases, it has become …

The last decade has witnessed great advances in our understanding of the genetic and
biological basis of childhood acute lymphoblastic leukemia (ALL), the development of …

Somatic genetic alterations of IKZF1, which encodes the lymphoid transcription factor
IKAROS, are common in high-risk B-progenitor acute lymphoblastic leukemia (ALL) and are …

Improvements in risk-directed treatment and supportive care, together with increased
reliance on both national and international collaborative studies, have made childhood …

There is increasing evidence for a strong inherited genetic basis of susceptibility to acute
lymphoblastic leukaemia (ALL) in children. To identify new risk variants for B-cell ALL (B …

Genomic analyses have revolutionized our understanding of the biology of B-progenitor
acute lymphoblastic leukemia (ALL). Studies of thousands of cases across the age spectrum …

Adolescents and young adults (AYAs, 15-39 years) with acute lymphoblastic leukemia (ALL)
represent a heterogeneous population who receive care in pediatric or adult cancer settings …

Advancement in the diagnosis and treatment of pedi-atric acute lymphoblastic leukemia
(ALL) is one of the greatest successes of modern medicine. Over the past 50 years, there …

Children with Down syndrome (DS) have a 20-fold increased risk of acute lymphoblastic
leukemia (ALL) and distinct somatic features, including CRLF2 rearrangement in∼ 50% of …

Defining genetic factors impacting chemotherapy failure can help to better predict response
and identify drug resistance mechanisms. However, there is limited understanding of the …